Treatment Options for Transplant-Ineligible Multiple Myeloma

Video

Nina Shah, MD, discusses the current treatment options for treating patients with transplant-ineligible multiple myeloma.

Nina Shah, MD: For transplant-ineligible patients, we traditionally had been using things like bortezomib [Velcade], lenalidomide [Revlimid], and dexamethasone, or VRd light, with lenalidomide maintenance therapy and that’s a perfectly good combination to use. The most recent MAIA trial [NCT02252172] data that were presented at the European [Hematology Association] Congress really did solidify the role for daratumumab [Darzalex], lenalidomide, dexamethasone in patients who are transplant-ineligible because there’s both a PFS [progression-free survival] and an overall survival advantage. It sounds like there’s going to be some nice quality-of-life data to suggest that these people are doing better despite being on therapy for longer.

Recent Videos
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Related Content
The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma

Roman Fabbricatore
September 22nd 2025
Article

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The investigators noted no new safety signals were reported in this trial.

Isa-VRd Meets Primary End Point in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Ariana Pelosci
September 20th 2025
Article

The VGPR or better rate was 87.8% in patients treated with Isa-VRd who had transplant-ineligible newly diagnosed multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Updated findings from AURIGA support the value of adding subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.

MRD Negativity Improves With Daratumumab Maintenance Combo in NDMM

Ashling Wahner
September 20th 2025
Article

Updated findings from AURIGA support the value of adding subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.

Phase 1b/2 BGB-11417-105 trial data showed low rates of high-grade infection and hematologic toxicity with sonrotoclax-based therapy in multiple myeloma.

Sonrotoclax Combo Shows Safety, Promising Efficacy in R/R Multiple Myeloma

Russ Conroy
September 20th 2025
Article

Phase 1b/2 BGB-11417-105 trial data showed low rates of high-grade infection and hematologic toxicity with sonrotoclax-based therapy in multiple myeloma.